Oblique Therapeutics and Eli Lilly Partner for Antibody Development

Oblique Therapeutics, a top biotech company focused on creating new drugs, has partnered with Eli Lilly and Company (Lilly) to use the AbiProt technology in developing antibodies for a valuable target. This collaboration is designed to speed up research and development for new treatments, with the potential to earn milestones and royalties if it proves successful.

Oblique will collaborate with Lilly Catalyze360-ExploR&D, an external innovation arm at Lilly that combines enterprise learning, scientific expertise, and top research and development skills to advance partner science.

The companies have an agreement signed in November 2023, which is already in place and now extends their collaboration to another valuable target.

“We are delighted to expand the collaboration between our companies and together create new science to address the unmet medical need in severe diseases. This collaboration with Lilly is of great importance to us and will further strengthen our position within the antibody discovery space,” says Christer Nordstedt, CEO at Oblique Therapeutics.

Oblique Therapeutics is a biotech company dedicated to creating innovative therapies for serious diseases, with a particular focus on pain management and other health issues. The company employs cutting-edge technology and creative research approaches to identify and develop novel antibody-based drug prospects.